NantHealth (NH) Misses Q1 EPS by 8c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/19/2026
- Wall St recovers as yields ease; Moderna lifts healthcare stocks
- U.S. Treasury doubles buyback operation size for long-dated bonds
- Marvell shares jump after giving Google warrants amid custom chip deal
- Nvidia credit risk gauge hits new peak as SoftBank readies record bond issue
- Deutsche Bank calls Treasury buyback doubling similar to ’operation twist’
- Marvell issues Google warrant tied to custom chip deal
- Tech selloff weighs down Wall Street as bond yields climb
- Lowe's Cos. (LOW) Tops Q2 EPS by 17c, Misses on Revenue; Offers Fy27 Guidance
- Nvidia or Sandisk? BofA reveals which stock is under-owned and which is crowded
- Francisco Partners to acquire Weave Communications for $650M
NantHealth Reports 2019 First-Quarter Financial Results
May 9, 2019 4:15 PM EDTTotal revenue in Q1 was $23.7 million, up 7% from Q1 2018 SaaS revenue of $17.8 million in Q1, up 10% from Q1 2018 and 3% sequentially Signed Substantial Three-year Eviti Contract with Multi-state Healthcare Payer Sequencing and Molecular Analysis, 820 total tests ordered in Q1, including 428 GPS Cancer® and 392 Liquid GPSSM Tests
CULVER CITY, Calif.--(BUSINESS WIRE)-- NantHealth, Inc. (NASDAQ-GS: NH), a next-generation, evidence-based, personalized healthcare company, today reported financial results for its first quarter ended March... More
